However, in reference to the CREATE-X, such comparison would have anyways been halted by the lack of distinctions in reporting baseline patients and diseases’ characteristics by molecular subtype, i.e., TNBC and HER2 negative luminal cancer patients. This evidence concerns the gene ERBB2 and cancer.